glycerol and Cough studies

Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.

Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.

Research Excerpts

Excerpt	Relevance	Reference
"In a double-blind trial, 29 patients were treated for stable, chronic bronchitis with iodinated glycerol (Organidin, 60 mg four times daily; n = 16) or placebo (n = 13)."	9.07	Treatment of stable chronic bronchitis with iodinated glycerol: a double-blind, placebo-controlled trial. ( Repsher, LH, 1993)
"In a double-blind trial, 29 patients were treated for stable, chronic bronchitis with iodinated glycerol (Organidin, 60 mg four times daily; n = 16) or placebo (n = 13)."	5.07	Treatment of stable chronic bronchitis with iodinated glycerol: a double-blind, placebo-controlled trial. ( Repsher, LH, 1993)
"Prior influenza vaccination had no effect on study outcome."	2.84	Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. ( Adkins, I; Arters, K; Buchheit, K; Esper, F; Ghannoum, MA; Mukherjee, PK; Salata, RA, 2017)
"An acute cough is usually consequent to upper respiratory tract infections and is self-resolving within a few weeks."	2.72	Acute cough in children and adolescents: A systematic review and a practical algorithm by the Italian Society of Pediatric Allergy and Immunology. ( Brambilla, I; Caffarelli, C; Calvani, M; Cardinale, F; Chiappini, E; Ciprandi, G; Cravidi, C; Del Giudice, MM; Duse, M; Licari, A; Manti, S; Marseglia, GL; Martelli, A; Minasi, D; Pajno, G; Peroni, DG; Tosca, MA, 2021)
"Many products for treating cough contain natural components."	2.72	Natural remedies for acute post-viral cough in children. ( Ciprandi, G; De Filippo, M; Marseglia, GL; Murgia, V; Tosca, MA; Votto, M, 2021)
" Safety endpoints included adverse events, hyperammonemic crises (HACs), and growth and development."	1.46	Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years. ( Berry, SA; Diaz, GA; Ficicioglu, C; Harding, CO; Lichter-Konecki, U; Longo, N; McCandless, SE; Robinson, B; Smith, WE; Vockley, J; Zori, R, 2017)

Research

Studies (10)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 0 Months to <2 Months Participants

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (20.00)	18.7374
1990's	2 (20.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	2 (20.00)	24.3611
2020's	3 (30.00)	2.80

Authors	Studies
Eccles, R	1
Marseglia, GL	2
Manti, S	1
Chiappini, E	1
Brambilla, I	1
Caffarelli, C	1
Calvani, M	1
Cardinale, F	1
Cravidi, C	1
Duse, M	1
Martelli, A	1
Minasi, D	1
Del Giudice, MM	1
Pajno, G	1
Peroni, DG	1
Tosca, MA	2
Licari, A	1
Ciprandi, G	2
Murgia, V	1
Votto, M	1
De Filippo, M	1
Berry, SA	1
Longo, N	1
Diaz, GA	1
McCandless, SE	1
Smith, WE	1
Harding, CO	1
Zori, R	1
Ficicioglu, C	1
Lichter-Konecki, U	1
Robinson, B	1
Vockley, J	1
Mukherjee, PK	1
Esper, F	1
Buchheit, K	1
Arters, K	1
Adkins, I	1
Ghannoum, MA	1
Salata, RA	1
Repsher, LH	1
Morgan, EJ	1
Petty, TL	1
Block, SH	1
Lewy, RB	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)[NCT02246218]	Phase 4	27 participants (Actual)	Interventional	2014-12-31	Completed
A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo to Prevent Acute Upper Respiratory Disease and Respiratory Virus Infections[NCT02644135]		100 participants (Actual)	Interventional	2013-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The percentage of participants with successful transition is based on Investigator response to the question, Has transition to 100% RAVICTI been successful with controlled ammonia? For participants < 2 months of age, after a minimum of 24 hours of ammonia monitoring following the first full dose of RAVICTI alone, the participant was effectively transitioned when following conditions were met: no signs and symptoms of hyperammonemia; ammonia level less than 100 μmol/L (without normalization of ammonia, ie, without conversion of values from local laboratories with varying normal ranges to standardized values); and eligible for discharge per Investigator judgment." (NCT02246218)
Timeframe: Up to Day 4

Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 2 Months to <2 Years Participants

Intervention	percentage of participants (Number)
RAVICTI: Age 0 to < 2 Months	100

"The percentage of participants with successful transition is based on Investigator response to the question, Has transition to 100% RAVICTI been successful with controlled ammonia? For participants 2 months of age and older, after a minimum of 24 hours of ammonia monitoring following the first full dose of RAVICTI alone, the participant was effectively transitioned when following conditions were met: no signs and symptoms of hyperammonemia; ammonia level less than 100 μmol/L (without normalization of ammonia, ie, without conversion of values from local laboratories with varying normal ranges to standardized values); and eligible for discharge per Investigator judgment." (NCT02246218)
Timeframe: Up to Day 4

Plasma PAA AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

Intervention	percentage of participants (Number)
RAVICTI: Age 2 Months to < 2 Years	100